Gen Kano1, Bruce S Bochner2, Nives Zimmermann3. 1. Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, United States; Department of Pediatrics, Kyoto Prefecture University of Medicine, Japan. 2. Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, United States. 3. Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, United States; Department of Pathology and Laboratory Medicine, University of Cincinnati, United States. Electronic address: nives.zimmermann@cchmc.org.
Abstract
RATIONALE: Siglec-8 is a surface receptor predominantly expressed on human eosinophils where its ligation induces reactive oxygen species (ROS) formation and cell death. Since Siglec-8 has intracellular tyrosine-based motifs, we hypothesized that Src family kinases (SFKs) are involved in ROS formation and cell death induced by Siglec-8 engagement. METHODS: Human peripheral blood eosinophils were purified and incubated with anti-Siglec-8 monoclonal antibodies (mAb, agonist), IL-5, and SFK pharmacological inhibitors. We focused on Siglec-8-induced cell death in short-term IL-5-activated cells leading to a regulated necrosis-type cell death. ROS production was determined by dihydrorhodamine (DHR) 123 labeling and flow cytometry, or by chemiluminescence using Amplex red. Activation of SFK was determined using phospholuminex and Western blotting. RESULTS: In order to determine cellular localization of ROS production, we measured intra and extracellular ROS. While an ETosis stimulus (calcium ionophore A23187) led to extracellular ROS (ecROS) production, Siglec-8-engagement in short-term IL-5 activated cells led to intracellular ROS (icROS) accumulation. Consistently, inhibition of extracellular ROS by catalase inhibited ETosis, but not IL-5-primed Siglec-8-induced cell death. In order to determine signaling events for Siglec-8, we performed Western blotting and found SFK phosphorylation in lysates from eosinophils stimulated with anti-Siglec-8 mAb±IL-5. In order to identify which SFKs were involved, we used the phospholuminex assay and found increased levels of phosphorylated Fgr in the cytoplasmic fraction of cells co-stimulated with anti-Siglec-8 and IL-5 for 3 hours compared with cells stimulated with IL-5 alone. To test the involvement of SFKs in ROS production and cell death, we used SFK inhibitors PP2 and dasatinib, both of which completely inhibited eosinophil ROS production and cell death induced by anti-Siglec-8 and IL-5 co-stimulation. CONCLUSION: Siglec-8 engagement in short-term IL-5-activated eosinophils causes icROS production and SKF phosphorylation, and both are essential in mediating Siglec-8-induced cell death.
RATIONALE: Siglec-8 is a surface receptor predominantly expressed on human eosinophils where its ligation induces reactive oxygen species (ROS) formation and cell death. Since Siglec-8 has intracellular tyrosine-based motifs, we hypothesized that Src family kinases (SFKs) are involved in ROS formation and cell death induced by Siglec-8 engagement. METHODS:Human peripheral blood eosinophils were purified and incubated with anti-Siglec-8 monoclonal antibodies (mAb, agonist), IL-5, and SFK pharmacological inhibitors. We focused on Siglec-8-induced cell death in short-term IL-5-activated cells leading to a regulated necrosis-type cell death. ROS production was determined by dihydrorhodamine (DHR) 123 labeling and flow cytometry, or by chemiluminescence using Amplex red. Activation of SFK was determined using phospholuminex and Western blotting. RESULTS: In order to determine cellular localization of ROS production, we measured intra and extracellular ROS. While an ETosis stimulus (calcium ionophore A23187) led to extracellular ROS (ecROS) production, Siglec-8-engagement in short-term IL-5 activated cells led to intracellular ROS (icROS) accumulation. Consistently, inhibition of extracellular ROS by catalase inhibited ETosis, but not IL-5-primed Siglec-8-induced cell death. In order to determine signaling events for Siglec-8, we performed Western blotting and found SFK phosphorylation in lysates from eosinophils stimulated with anti-Siglec-8 mAb±IL-5. In order to identify which SFKs were involved, we used the phospholuminex assay and found increased levels of phosphorylated Fgr in the cytoplasmic fraction of cells co-stimulated with anti-Siglec-8 and IL-5 for 3 hours compared with cells stimulated with IL-5 alone. To test the involvement of SFKs in ROS production and cell death, we used SFK inhibitors PP2 and dasatinib, both of which completely inhibited eosinophil ROS production and cell death induced by anti-Siglec-8 and IL-5 co-stimulation. CONCLUSION:Siglec-8 engagement in short-term IL-5-activated eosinophils causes icROS production and SKF phosphorylation, and both are essential in mediating Siglec-8-induced cell death.
Authors: Rebeca Acín-Pérez; Isabel Carrascoso; Francesc Baixauli; Marta Roche-Molina; Ana Latorre-Pellicer; Patricio Fernández-Silva; María Mittelbrunn; Francisco Sanchez-Madrid; Acisclo Pérez-Martos; Clifford A Lowell; Giovanni Manfredi; José Antonio Enríquez Journal: Cell Metab Date: 2014-05-22 Impact factor: 27.287
Authors: Benjamin E Tourdot; Michelle K Brenner; Kathleen C Keough; Trudy Holyst; Peter J Newman; Debra K Newman Journal: Biochemistry Date: 2013-04-03 Impact factor: 3.162
Authors: N Vanlangenakker; T Vanden Berghe; P Bogaert; B Laukens; K Zobel; K Deshayes; D Vucic; S Fulda; P Vandenabeele; M J M Bertrand Journal: Cell Death Differ Date: 2010-11-05 Impact factor: 15.828
Authors: Takumi Kiwamoto; Toshihiko Katoh; Michael Tiemeyer; Bruce S Bochner; Christopher M Evans; William J Janssen; Mary E Brummet; Sherry A Hudson; Zhou Zhu Journal: J Allergy Clin Immunol Date: 2014-12-12 Impact factor: 10.793
Authors: Ramin Lotfi; Gloria Isabelle Herzog; Richard Anthony DeMarco; Donna Beer-Stolz; James Joseph Lee; Anna Rubartelli; Hubert Schrezenmeier; Michael Thomas Lotze Journal: J Immunol Date: 2009-09-30 Impact factor: 5.422
Authors: Shigeharu Ueki; Rossana C N Melo; Ionita Ghiran; Lisa A Spencer; Ann M Dvorak; Peter F Weller Journal: Blood Date: 2013-01-09 Impact factor: 22.113
Authors: Mats W Johansson; Elizabeth A Kelly; Christopher L Nguyen; Nizar N Jarjour; Bruce S Bochner Journal: Int Arch Allergy Immunol Date: 2018-06-07 Impact factor: 2.749
Authors: Daniela J Carroll; Jeremy A O'Sullivan; David B Nix; Yun Cao; Michael Tiemeyer; Bruce S Bochner Journal: J Allergy Clin Immunol Date: 2017-09-06 Impact factor: 10.793